Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harbin Pharmaceutical Group Co's EBIT per Share for the
three
months ended in Mar. 2026 was ¥0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.21.
During the past 12 months, the average EBIT per Share Growth Rate of Harbin Pharmaceutical Group Co was -33.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 3.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Harbin Pharmaceutical Group Co's EBIT per Share or its related term are showing as below:
SHSE:600664'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -40.5 Med: 5.3 Max: 42
Current: 3.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Harbin Pharmaceutical Group Co was 42.00% per year. The lowest was -40.50% per year. And the median was 5.30% per year.
SHSE:600664's 3-Year EBIT Growth Rate is ranked worse than 57.51% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs SHSE:600664: 3.50
Harbin Pharmaceutical Group Co (SHSE:600664) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Harbin Pharmaceutical Group Co EBIT per Share Related Terms
Harbin Pharmaceutical Group Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Pharmaceutical Group Co EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Pharmaceutical Group Co (SHSE:600664) has a EBIT per Share of ¥0.21 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Harbin Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Harbin Pharmaceutical Group Co ranks #467 out of 812 companies in the Drug Manufacturers industry, placing it in the top 57.5%.
Is Harbin Pharmaceutical Group Co's EBIT per Share too high?
Harbin Pharmaceutical Group Co's current EBIT per Share is ¥0.21. Based on the distribution chart, Harbin Pharmaceutical Group Co ranks #467 out of 812 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Harbin Pharmaceutical Group Co ranks #467 out of 812 companies for EBIT per Share. This places Harbin Pharmaceutical Group Co in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Harbin Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current EBIT per Share is ¥0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥5.40 — trading 53.8% above its estimated fair value. The current EBIT per Share is ¥0.21. Harbin Pharmaceutical Group Co's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current EBIT per Share is ¥0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥5.40 is trading 53.8% above its estimated GF Value™ of ¥3.51.
GuruFocus considers Harbin Pharmaceutical Group Co to be Significantly Overvalued.
Key valuation signals for SHSE:600664:
EBIT per Share: ¥0.21
GF Value™: ¥3.51 vs. price of ¥5.40 (53.8% above fair value)
No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harbin Pharmaceutical Group Co Business Description
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
66GF Score
Get the complete analysis for SHSE:600664
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600664 has been successfully added to your 
